Supplemental New Drug Application Submitted for Nubeqa in …
WEB20 hours ago — A supplemental new drug application has been submitted to the Food and Drug Administration (FDA) for Nubeqa (darolutamide) plus androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer. “Simply put, our ambition is to help more patients with prostate cancer,” Christine Roth, Executive Vice President of ...
Insights into testosterone recovery after androgen deprivation therapy ...
WEB1 day ago — A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy ...
Bayer submits application to U.S. FDA for third indication of …
WEB2 days ago — Berlin, September 26, 2024 – Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy …
Advancements in Androgen Deprivation Therapy - AUANews
WEBMar 9, 2023 — Androgen deprivation therapy (ADT) has served as the backbone of treatment for advanced prostate cancer (APC) since Charles Huggins’ discovery of its inhibitory effect on prostate cancer in 1941. With recent FDA (Food and Drug Administration) approvals of novel hormonal therapies (NHTs) for androgen blockade and newly published data ...
FDA Approves Relugolix for Advanced Prostate Cancer
WEBJan 26, 2021 — Known as androgen deprivation therapy (ADT), these treatments are akin to putting a stopper in a car’s gas tank: robbing prostate tumors of the fuel they need to grow and spread.
Bipolar Androgen Therapy Trials Under Way - Johns Hopkins Medicine
WEBDec 12, 2023 — Denmeade and colleagues within the Prostate Cancer Research Program are testing BAT in several clinical trials: The ACROBAT study is testing the rapid cycling of an oral form of testosterone in men whose cancer has just progressed to the castrate-resistant state (CRPC).
Androgen deprivation therapy combined with postoperative …
WEBJun 1, 2024 — Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation ...
WEBSAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
Androgen deprivation therapy exacerbates Alzheimer’s …
WEBJun 21, 2024 — Androgen deprivation therapy (ADT) for prostate cancer is associated with an increased risk of dementia, including Alzheimer’s disease (AD). The mechanistic connection between ADT and AD-related cognitive impairment in patients with prostate cancer remains elusive.
Second generation anti-androgens and androgen deprivation therapy …
WEBOct 6, 2022 — Recently updated American Society for Clinical Oncology (ASCO) evidence-based guidelines and the National Comprehensive Cancer Network (NCCN) Guidelines have updated recommendations for the...